8 completed. 8 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 8 |
| Phase 1 | 3 | Completed 3 |
Follow SCLC: new trials by email Literature Review of SCLC trials Research Report on SCLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors Berzosertib, Sacituzumab Govitecan - HRD Cancer, SCLC | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 35 | 2021-09-20 | 2026-07-21 |
| Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2] AZD6738, Olaparib - SCLC | Phase 2 | Completed | Samsung Medical Center | 26 | 2018-10-17 | 2021-02-18 |
| A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Nivolumab, Plinabulin, Ipilimumab - Lung Cancer, SCLC | Phase 1 / Phase 2 | Completed | Salma Sabbour | 39 | 2018-09-06 | 2026-01-20 |
| Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors Lurbinectedin, Irinotecan - Advanced Solid Tumors, Glioblastoma | Phase 1 / Phase 2 | Completed | PharmaMar | 316 | 2016-05-06 | 2025-07-09 |
| Pazopanib Maintenance for SCLC Pazopanib, Placebo - SCLC | Phase 2 | Completed | Samsung Medical Center | 97 | 2013-06-01 | 2019-12-09 |
| Pazopanib in Relapsed and Refractory Small Cell Lung Cancer Pazopanib - SCLC | Phase 2 | Completed | Hellenic Oncology Research Group | 58 | 2011-11-01 | 2015-10-08 |
| Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer Pazopanib - Small Cell Lung Cancer, Lung Cancer | Phase 2 | Completed | Dana-Farber Cancer Institute | 33 | 2010-06-01 | 2019-04-23 |
| Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer OSI-211 (Liposomal Lurtotecan) - SCLC, Carcinoma, Small Cell | Phase 2 | Completed | Astellas Pharma Inc | 47 | 2002-09-01 | 2011-10-20 |
Lung Neoplasms (2) · Small Cell Lung Carcinoma (2) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Small Cell (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Glioblastoma (1) · Mesothelioma (1) · Neoplasms (1) · Neuroendocrine Tumors (1) · Recurrence (1) · Sarcoma (1) · Stomach Neoplasms (1)
Neoplasms by Site (4) · Lung Diseases (3) · Neoplasms (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3) · Bronchial Neoplasms (2) · Carcinoma (2) · Carcinoma, Bronchogenic (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Adenoma (1) · Adnexal Diseases (1) · Astrocytoma (1) · Colonic Diseases (1)
pazopanib (3) · Ipilimumab (1) · Irinotecan (1) · NPI 2358 (1) · Nivolumab (1) · PM 01183 (1) · berzosertib (1) · ceralasertib (1) · lurtotecan (1) · olaparib (1) · sacituzumab govitecan (1)
Samsung Medical Center (2) · Astellas Pharma Inc (1) · Dana-Farber Cancer Institute (1) · Hellenic Oncology Research Group (1) · National Cancer Institute (NCI) (1) · PharmaMar (1) · Salma Sabbour (1)
United States (5) · South Korea (2) · France (1) · Germany (1) · Greece (1) · Italy (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Anish Thomas, M.D. (1) · David Jackman, MD (1) · Salma Jabbour, MD (1)